412 related articles for article (PubMed ID: 34523245)
1. Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
Sagahón-Azúa J; Medellín-Garibay SE; Chávez-Castillo CE; González-Salinas CG; Milán-Segovia RDC; Romano-Moreno S
Pharmacol Res Perspect; 2021 Oct; 9(5):e00864. PubMed ID: 34523245
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.
LLerena A; Dorado P; Berecz R; González AP; Peñas-LLedó EM
Eur J Clin Pharmacol; 2004 Feb; 59(12):869-73. PubMed ID: 14726986
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
[TBL] [Abstract][Full Text] [Related]
4. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response.
Jannuzzi G; Gatti G; Magni P; Spina E; Pacifici R; Zuccaro P; Torta R; Guarneri L; Perucca E
Ther Drug Monit; 2002 Oct; 24(5):616-27. PubMed ID: 12352933
[TBL] [Abstract][Full Text] [Related]
5. Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients.
LLerena A; Dorado P; Berecz R; González A; Jesús Norberto M; de la Rubia A; Cáceres M
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):25-31. PubMed ID: 12450521
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Fluoxetine and Norfluoxetine Pharmacokinetic Profiles Using Physiologically Based Pharmacokinetic Modeling.
Jeong HC; Chae YJ; Lee S; Kang W; Yun HY; Shin KH
J Clin Pharmacol; 2021 Nov; 61(11):1505-1513. PubMed ID: 34118174
[TBL] [Abstract][Full Text] [Related]
7. Distribution and excretion of fluoxetine and norfluoxetine in human milk.
Kristensen JH; Ilett KF; Hackett LP; Yapp P; Paech M; Begg EJ
Br J Clin Pharmacol; 1999 Oct; 48(4):521-7. PubMed ID: 10583022
[TBL] [Abstract][Full Text] [Related]
8. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects.
Liu ZQ; Cheng ZN; Huang SL; Chen XP; Ou-Yang DS; Jiang CH; Zhou HH
Br J Clin Pharmacol; 2001 Jul; 52(1):96-9. PubMed ID: 11453896
[TBL] [Abstract][Full Text] [Related]
9. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.
Sager JE; Lutz JD; Foti RS; Davis C; Kunze KL; Isoherranen N
Clin Pharmacol Ther; 2014 Jun; 95(6):653-62. PubMed ID: 24569517
[TBL] [Abstract][Full Text] [Related]
10. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
[TBL] [Abstract][Full Text] [Related]
11. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers.
Harvey AT; Preskorn SH
J Clin Psychopharmacol; 2001 Apr; 21(2):161-6. PubMed ID: 11270912
[TBL] [Abstract][Full Text] [Related]
12. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-)genetic factors.
Magalhães P; Alves G; Fortuna A; Llerena A; Falcão A;
Exp Clin Psychopharmacol; 2020 Oct; 28(5):589-600. PubMed ID: 31750687
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of selective serotonin reuptake inhibitors.
Hiemke C; Härtter S
Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
[TBL] [Abstract][Full Text] [Related]
15. Effects of CYP2C19 Variants on Fluoxetine Metabolism in vitro.
Fang P; He JY; Han AX; Lan T; Dai DP; Cai JP; Hu GX
Pharmacology; 2017; 100(1-2):91-97. PubMed ID: 28494448
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia.
Stedman CA; Begg EJ; Kennedy MA; Roberts R; Wilkinson TJ
Hum Psychopharmacol; 2002 Jun; 17(4):187-90. PubMed ID: 12404686
[TBL] [Abstract][Full Text] [Related]
17. The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics.
Piergies AA; Sweet J; Johnson M; Roth-Schechter BF; Allard S
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):178-83. PubMed ID: 8861737
[TBL] [Abstract][Full Text] [Related]
18. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
Fjordside L; Jeppesen U; Eap CB; Powell K; Baumann P; Brøsen K
Pharmacogenetics; 1999 Feb; 9(1):55-60. PubMed ID: 10208643
[TBL] [Abstract][Full Text] [Related]
19. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin.
Hamelin BA; Turgeon J; Vallée F; Bélanger PM; Paquet F; LeBel M
Clin Pharmacol Ther; 1996 Nov; 60(5):512-21. PubMed ID: 8941024
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration.
Sawyer EK; Howell LL
Pharmacology; 2011; 88(1-2):44-9. PubMed ID: 21757974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
